Publications by authors named "Klaus Dugi"

Claim this Profile
C
Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer: The PRONOUNCE Trial Study Design.
Chiara Melloni, Susan F Slovin, Allan Blemings, Shaun G Goodman, Christopher P Evans, Klaus Dugi

JACC CardioOncol· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral N-acetylcysteine reduces plasma homocysteine concentrations regardless of lipid or smoking status.
Wulf Hildebrandt, Roland Sauer, Gabriel Bonaterra, Klaus A Dugi, Lutz Edler

Am J Clin Nutr· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dosing Recommendations for New Oral Anticoagulants.
Jörg Kreuzer, Klaus Dugi

JAMA· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of TCF7L2 gene variants on the therapeutic response to the dipeptidylpeptidase-4 inhibitor linagliptin.
Heike Zimdahl, Carina Ittrich, Ulrike Graefe-Mody, Bernhard O Boehm, Michael Mark, Klaus A Dugi

Diabetologia· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in healthy Japanese subjects.
Akiko Sarashina, Kazuki Koiwai, Leo J Seman, Norio Yamamura, Atsushi Taniguchi, Klaus A Dugi

Drug Metab Pharmacokinet· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association between a gene variant near ataxia telangiectasia mutated and coronary artery disease in men.
Stephan Schiekofer, Izabela Bobak, Marcus E Kleber, Winfried Maerz, Gottfried Rudofsky, Klaus A Dugi

Diab Vasc Dis Res· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus.
Tim Heise, Leo Seman, Sreeraj Macha, Peter Jones, Alexandra Marquart, Klaus Dugi

Diabetes Ther· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The epidemiological Boehringer Ingelheim Employee study--part I: impact of overweight and obesity on cardiometabolic risk.
Kerstin Kempf, Stephan Martin, Carmen Döhring, Klaus Dugi, Carolin Wolfram von Wolmar

J Obes· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects.
Leo Seman, Sreeraj Macha, Gerhard Nehmiz, Gudrun Simons, Bailuo Ren, Klaus Dugi

Clin Pharmacol Drug Dev· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus.
Thomas Rauch, Ulrike Graefe-Mody, Carolyn F Deacon, Arne Ring, Jens J Holst, Klaus A Dugi

Diabetes Ther· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial.
Baptist Gallwitz, Julio Rosenstock, Thomas Rauch, Sudipta Bhattacharya, Sanjay Patel, Klaus A Dugi

Lancet· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MRP8/14 is associated with systemic inflammation in stable coronary atherosclerosis in men.
Marcus Baumann, Christoph Schmaderer, Klaus Burkhardt, Bernhard Haller, Uwe Heemann, Klaus Dugi

Eur J Clin Invest· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The DPP-4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses.
Arne Ring, Andreas Port, E Ulrike Graefe-Mody, Ivette Revollo, Mario Iovino, Klaus A Dugi

Br J Clin Pharmacol· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients.
Yoshiharu Horie, Shigeto Kanada, Hirotaka Watada, Akiko Sarashina, Atsushi Taniguchi, Klaus A Dugi

Clin Ther· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects.
Silke Retlich, Vincent Duval, Arne Ring, Alexander Staab, Silke Hüttner, Klaus A Dugi

Clin Pharmacokinet· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Akiko Sarashina, Shogo Sesoko, Mitsuyoshi Nakashima, Naoyuki Hayashi, Atsushi Taniguchi, Klaus A Dugi

Clin Ther· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, statistical analysis and sample size calculation of a phase IIb/III study of linagliptin versus voglibose and placebo.
Yoshiharu Horie, Naoyuki Hayashi, Klaus Dugi, Masahiro Takeuchi

Trials· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PPAR gamma variant influences angiographic outcome and 10-year cardiovascular risk in male symptomatic coronary artery disease patients: response to Regieli et al.
Jochen G Schneider, Stephan Schiekofer, Maximilian von Eynatten, Klaus A Dugi

Diabetes Care· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-molecular weight adiponectin is independently associated with the extent of coronary artery disease in men.
Maximilian von Eynatten, Per M Humpert, Annabelle Bluemm, Philipp M Lepper, Andreas Hamann, Klaus A Dugi

Atherosclerosis· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased gene expression of scavenger receptors and proinflammatory markers in peripheral blood mononuclear cells of hyperlipidemic males.
Gabriel A Bonaterra, Wulf Hildebrandt, Anne Bodens, Roland Sauer, Klaus A Dugi

J Mol Med (Berl)· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum adiponectin levels are an independent predictor of the extent of coronary artery disease in men.
Maximilian von Eynatten, Jochen G Schneider, Per M Humpert, Joerg Kreuzer, Helmut Kuecherer, Klaus A Dugi

J Am Coll Cardiol· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atorvastatin increases lipoprotein lipase expression in vitro and activity in vivo.
Jochen G Schneider, Maximilian V Eynatten, Klaus A Dugi

J Atheroscler Thromb· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low plasma adiponectin levels are associated with increased hepatic lipase activity in vivo.
Jochen G Schneider, Maximilian von Eynatten, Stephan Schiekofer, Peter P Nawroth, Klaus A Dugi

Diabetes Care· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adipocytokines as a novel target for the anti-inflammatory effect of atorvastatin in patients with type 2 diabetes.
Maximilian von Eynatten, Jochen G Schneider, Senad Hadziselimovic, Andreas Hamann, Angelika Bierhaus, Klaus A Dugi

Diabetes Care· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased cyclooxygenase-2 expression in peripheral blood mononuclear cells of smokers and hyperlipidemic subjects.
Gabriel A Bonaterra, Wulf Hildebrandt, Anne Bodens, Roland Sauer, Klaus A Dugi

Free Radic Biol Med· January 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis